Gianluigi Tanda, Ph.D.

@article{pmid37466616,

title = {An FSCV Study on the Effects of Targeted Typical and Atypical DAT Inhibition on Dopamine Dynamics in the Nucleus Accumbens Shell of Male and Female Mice},

author = {Melinda Hersey and Andy Y Chen and Mattingly K Bartole and Jayati Anand and Amy Hauck Newman and Gianluigi Tanda},

url = {https://pubmed.ncbi.nlm.nih.gov/37466616/},

doi = {10.1021/acschemneuro.3c00354},

issn = {1948-7193},

year  = {2023},

date = {2023-08-01},

urldate = {2023-08-01},

journal = {ACS Chem Neurosci},

volume = {14},

number = {15},

pages = {2802--2810},

abstract = {Understanding the neurochemistry underlying sex differences in psychostimulant use disorders (PSUD) is essential for developing related therapeutics. Many psychostimulants, like cocaine, inhibit the dopamine transporter (DAT), which is largely thought to account for actions related to their misuse and dependence. Cocaine-like, typical DAT inhibitors preferentially bind DAT in an outward-facing conformation, while atypical DAT inhibitors, like modafinil, prefer a more inward-facing DAT conformation. Modafinil and -modafinil have emerged as potential therapeutic options for selected populations of individuals affected by PSUD. In addition, analogs of modafinil (JJC8-088 and JJC8-091) with different pharmacological profiles have been explored as potential PSUD medications in preclinical models. In this work, we employ fast scan cyclic voltammetry (FSCV) to probe nucleus accumbens shell (NAS) dopamine (DA) dynamics in C57BL/6 male and female mice. We find that cocaine slowed DA clearance in both male and female mice but produced more robust increases in evoked NAS DA in female mice. -Modafinil produced mild increases in evoked NAS DA and slowed DA clearance across the sexes. The modafinil analog JJC8-088, a typical DAT inhibitor, produced increases in evoked NAS DA in female and male mice. Finally, JJC8-091, an atypical DAT inhibitor, produced limited increases in evoked NAS DA and slowed DA clearance in both sexes. In this work we begin to tease out how sex differences may alter the effects of DAT targeting and highlight how this may help focus research toward effective treatment options for PSUD.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid37446929,

title = {Are There Prevalent Sex Differences in Psychostimulant Use Disorder? A Focus on the Potential Therapeutic Efficacy of Atypical Dopamine Uptake Inhibitors},

author = {Melinda Hersey and Mattingly K Bartole and Claire S Jones and Amy Hauck Newman and Gianluigi Tanda},

url = {https://pubmed.ncbi.nlm.nih.gov/37446929/},

doi = {10.3390/molecules28135270},

issn = {1420-3049},

year  = {2023},

date = {2023-07-01},

urldate = {2023-07-01},

journal = {Molecules},

volume = {28},

number = {13},

abstract = {Psychostimulant use disorders (PSUD) affect a growing number of men and women and exert sizable public health and economic burdens on our global society. Notably, there are some sex differences in the onset of dependence, relapse rates, and treatment success with PSUD observed in preclinical and clinical studies. The subtle sex differences observed in the behavioral aspects of PSUD may be associated with differences in the neurochemistry of the dopaminergic system between sexes. Preclinically, psychostimulants have been shown to increase synaptic dopamine (DA) levels and may downregulate the dopamine transporter (DAT). This effect is greatest in females during the high estradiol phase of the estrous cycle. Interestingly, women have been shown to be more likely to begin drug use at younger ages and report higher levels of desire to use cocaine than males. Even though there is currently no FDA-approved medication, modafinil, a DAT inhibitor approved for use in the treatment of narcolepsy and sleep disorders, has shown promise in the treatment of PSUD among specific populations of affected individuals. In this review, we highlight the therapeutic potential of modafinil and other atypical DAT inhibitors focusing on the lack of sex differences in the actions of these agents.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid37311803b,

title = {Interactions of calmodulin kinase II with the dopamine transporter facilitate cocaine-induced enhancement of evoked dopamine release},

author = {Jacqueline D Keighron and Jordi Bonaventura and Yang Li and Jae-Won Yang and Emily M DeMarco and Melinda Hersey and Jianjing Cao and Walter Sandtner and Michael Michaelides and Harald H Sitte and Amy Hauck Newman and Gianluigi Tanda},

url = {https://pubmed.ncbi.nlm.nih.gov/37311803/},

doi = {10.1038/s41398-023-02493-4},

issn = {2158-3188},

year  = {2023},

date = {2023-06-01},

urldate = {2023-06-01},

journal = {Transl Psychiatry},

volume = {13},

number = {1},

pages = {202},

abstract = {Typical and atypical dopamine uptake inhibitors (DUIs) prefer distinct conformations of the dopamine transporter (DAT) to form ligand-transporter complexes, resulting in markedly different effects on behavior, neurochemistry, and potential for addiction. Here we show that cocaine and cocaine-like typical psychostimulants elicit changes in DA dynamics distinct from those elicited by atypical DUIs, as measured via voltammetry procedures. While both classes of DUIs reduced DA clearance rate, an effect significantly related to their DAT affinity, only typical DUIs elicited a significant stimulation of evoked DA release, an effect unrelated to their DAT affinity, which suggests a mechanism of action other than or in addition to DAT blockade. When given in combination, typical DUIs enhance the stimulatory effects of cocaine on evoked DA release while atypical DUIs blunt them. Pretreatments with an inhibitor of CaMKIIα, a kinase that interacts with DAT and that regulates synapsin phosphorylation and mobilization of reserve pools of DA vesicles, blunted the effects of cocaine on evoked DA release. Our results suggest a role for CaMKIIα in modulating the effects of cocaine on evoked DA release without affecting cocaine inhibition of DA reuptake. This effect is related to a specific DAT conformation stabilized by cocaine. Moreover, atypical DUIs, which prefer a distinct DAT conformation, blunt cocaine's neurochemical and behavioral effects, indicating a unique mechanism underlying their potential as medications for treating psychostimulant use disorder.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid37311803,

title = {Interactions of calmodulin kinase II with the dopamine transporter facilitate cocaine-induced enhancement of evoked dopamine release},

author = {Jacqueline D Keighron and Jordi Bonaventura and Yang Li and Jae-Won Yang and Emily M DeMarco and Melinda Hersey and Jianjing Cao and Walter Sandtner and Michael Michaelides and Harald H Sitte and Amy Hauck Newman and Gianluigi Tanda},

url = {https://pubmed.ncbi.nlm.nih.gov/37311803/},

doi = {10.1038/s41398-023-02493-4},

issn = {2158-3188},

year  = {2023},

date = {2023-06-01},

urldate = {2023-06-01},

journal = {Transl Psychiatry},

volume = {13},

number = {1},

pages = {202},

abstract = {Typical and atypical dopamine uptake inhibitors (DUIs) prefer distinct conformations of the dopamine transporter (DAT) to form ligand-transporter complexes, resulting in markedly different effects on behavior, neurochemistry, and potential for addiction. Here we show that cocaine and cocaine-like typical psychostimulants elicit changes in DA dynamics distinct from those elicited by atypical DUIs, as measured via voltammetry procedures. While both classes of DUIs reduced DA clearance rate, an effect significantly related to their DAT affinity, only typical DUIs elicited a significant stimulation of evoked DA release, an effect unrelated to their DAT affinity, which suggests a mechanism of action other than or in addition to DAT blockade. When given in combination, typical DUIs enhance the stimulatory effects of cocaine on evoked DA release while atypical DUIs blunt them. Pretreatments with an inhibitor of CaMKIIα, a kinase that interacts with DAT and that regulates synapsin phosphorylation and mobilization of reserve pools of DA vesicles, blunted the effects of cocaine on evoked DA release. Our results suggest a role for CaMKIIα in modulating the effects of cocaine on evoked DA release without affecting cocaine inhibition of DA reuptake. This effect is related to a specific DAT conformation stabilized by cocaine. Moreover, atypical DUIs, which prefer a distinct DAT conformation, blunt cocaine's neurochemical and behavioral effects, indicating a unique mechanism underlying their potential as medications for treating psychostimulant use disorder.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid36420597,

title = {Oxytocin receptors mediate oxytocin potentiation of methylphenidate-induced stimulation of accumbens dopamine in rats},

author = {Melinda Hersey and Amanda K Bacon and Lydia G Bailey and Mary R Lee and Andy Y Chen and Lorenzo Leggio and Gianluigi Tanda},

url = {https://pubmed.ncbi.nlm.nih.gov/36420597/},

doi = {10.1111/jnc.15730},

issn = {1471-4159},

year  = {2023},

date = {2023-03-01},

urldate = {2023-03-01},

journal = {J Neurochem},

volume = {164},

number = {5},

pages = {613--623},

abstract = {While the illicit use and misuse of stimulants like cocaine and methylphenidate (MP) has increased, there remains no FDA-approved treatments for psychostimulant use disorders (PSUD). Oxytocin (OT) has shown promise as a potential pharmacotherapy for PSUD. Dopamine (DA) neurotransmission plays a significant role in PSUD. We have recently shown that OT blunts the reinforcing effects of MP but, surprisingly, enhanced MP-induced stimulation of DA levels. Such effects have been suggested as a result of activation of OT receptors or, alternatively, could be mediated by direct actions of OT on MP blockade of the DA transporter. Here, we employed fast scan cyclic voltammetry (FSCV) to investigate the effects of systemic OT on MP-induced changes in the dynamics of DA, phasic release and uptake, in the nucleus accumbens shell (NAS) of Sprague-Dawley rats. We also tested the systemic effects of an antagonist of OT receptors, atosiban, to counteract the OT enhancement of dopaminergic effects of MP under microdialysis procedures in the NAS in rats. Administration of OT alone (2 mg/kg; i.p.) did not significantly modify evoked NAS DA dynamics measured by FSCV, and when administered 10 min before MP (0.1, 0.3, 1.0 mg/kg; i.v.), OT did not potentiate MP-induced increases in phasic DA release and did not alter DA clearance rate, suggesting no direct interactions of OT with the MP-induced blockade of DA uptake. Also, OT alone did not elicit significant changes in tonic, extracellular NAS DA levels measured by microdialysis. However, consistent with previous studies, we observed that OT pretreatments (2 mg/kg; i.p.) potentiated MP-induced (0.1, 0.3, 1.0 mg/kg; i.v.) efflux of extracellular NAS DA levels. This effect was abolished when rats were pretreated with atosiban (2 mg/kg; i.p.), suggesting that OT receptors mediate this OT action. Overall, our results suggest that OT receptors mediated OT potentiation of MP-induced stimulation of extracellular NAS DA levels, likely driven by modulation of DA receptor signaling pathways, without affecting MP blockade of DAT.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid34750356b,

title = {Synaptic Zn^{2+} potentiates the effects of cocaine on striatal dopamine neurotransmission and behavior},

author = {Juan L Gomez and Jordi Bonaventura and Jacqueline Keighron and Kelsey M Wright and Dondre L Marable and Lionel A Rodriguez and Sherry Lam and Meghan L Carlton and Randall J Ellis and Chloe J Jordan and Guo-Hua Bi and Oscar Solis and Marco Pignatelli and Michael J Bannon and Zheng-Xiong Xi and Gianluigi Tanda and Michael Michaelides},

url = {https://pubmed.ncbi.nlm.nih.gov/34750356/},

doi = {10.1038/s41398-021-01693-0},

issn = {2158-3188},

year  = {2021},

date = {2021-11-01},

urldate = {2021-11-01},

journal = {Transl Psychiatry},

volume = {11},

number = {1},

pages = {570},

abstract = {Cocaine binds to the dopamine (DA) transporter (DAT) to regulate cocaine reward and seeking behavior. Zinc (Zn) also binds to the DAT, but the in vivo relevance of this interaction is unknown. We found that Zn concentrations in postmortem brain (caudate) tissue from humans who died of cocaine overdose were significantly lower than in control subjects. Moreover, the level of striatal Zn content in these subjects negatively correlated with plasma levels of benzoylecgonine, a cocaine metabolite indicative of recent use. In mice, repeated cocaine exposure increased synaptic Zn concentrations in the caudate putamen (CPu) and nucleus accumbens (NAc). Cocaine-induced increases in Zn were dependent on the Zn transporter 3 (ZnT3), a neuronal Zn transporter localized to synaptic vesicle membranes, as ZnT3 knockout (KO) mice were insensitive to cocaine-induced increases in striatal Zn. ZnT3 KO mice showed significantly lower electrically evoked DA release and greater DA clearance when exposed to cocaine compared to controls. ZnT3 KO mice also displayed significant reductions in cocaine locomotor sensitization, conditioned place preference (CPP), self-administration, and reinstatement compared to control mice and were insensitive to cocaine-induced increases in striatal DAT binding. Finally, dietary Zn deficiency in mice resulted in decreased striatal Zn content, cocaine locomotor sensitization, CPP, and striatal DAT binding. These results indicate that cocaine increases synaptic Zn release and turnover/metabolism in the striatum, and that synaptically released Zn potentiates the effects of cocaine on striatal DA neurotransmission and behavior and is required for cocaine-primed reinstatement. In sum, these findings reveal new insights into cocaine's pharmacological mechanism of action and suggest that Zn may serve as an environmentally derived regulator of DA neurotransmission, cocaine pharmacodynamics, and vulnerability to cocaine use disorders.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid34392304,

title = {Elevated body fat increases amphetamine accumulation in brain: evidence from genetic and diet-induced forms of adiposity},

author = {Xiuping Fu and Aparna P Shah and Jacqueline Keighron and Ta-Chung M Mou and Bruce Ladenheim and Jesse Alt and Daisuke Fukudome and Minae Niwa and Kellie L Tamashiro and Gianluigi Tanda and Akira Sawa and Jean-Lud Cadet and Rana Rais and Jay M Baraban},

url = {https://pubmed.ncbi.nlm.nih.gov/34392304/},

doi = {10.1038/s41398-021-01547-9},

issn = {2158-3188},

year  = {2021},

date = {2021-08-01},

urldate = {2021-08-01},

journal = {Transl Psychiatry},

volume = {11},

number = {1},

pages = {427},

abstract = {Despite the high prevalence of obesity, little is known about its potential impact on the pharmacokinetics of psychotropic drugs. In the course of investigating the role of the microRNA system on neuronal signaling, we found that mice lacking the translin/trax microRNA-degrading enzyme display an exaggerated locomotor response to amphetamine. As these mice display robust adiposity in the context of normal body weight, we checked whether this phenotype might reflect elevated brain levels of amphetamine. To assess this hypothesis, we compared plasma and brain amphetamine levels of wild type and Tsn KO mice. Furthermore, we checked the effect of diet-induced increases in adiposity on plasma and brain amphetamine levels in wild type mice. Brain amphetamine levels were higher in Tsn KO mice than in wild type littermates and correlated with adiposity. Analysis of the effect of diet-induced increases in adiposity in wild type mice on brain amphetamine levels also demonstrated that brain amphetamine levels correlate with adiposity. Increased adiposity displayed by Tsn KO mice or by wild type mice fed a high-fat diet correlates with elevated brain amphetamine levels. As amphetamine and its analogues are widely used to treat attention deficit disorder, which is associated with obesity, further studies are warranted to assess the impact of adiposity on amphetamine levels in these patients.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid33414501,

title = {Cocaine-induced locomotor stimulation involves autophagic degradation of the dopamine transporter},

author = {Maged M Harraz and Prasun Guha and In Guk Kang and Evan R Semenza and Adarsha P Malla and Young Jun Song and Luke Reilly and Isaac Treisman and Pedro Cortés and Mark A Coggiano and Vijayabhaskar Veeravalli and Rana Rais and Gianluigi Tanda and Solomon H Snyder},

url = {https://pubmed.ncbi.nlm.nih.gov/33414501/},

doi = {10.1038/s41380-020-00978-y},

issn = {1476-5578},

year  = {2021},

date = {2021-02-01},

urldate = {2021-02-01},

journal = {Mol Psychiatry},

volume = {26},

number = {2},

pages = {370--382},

abstract = {Cocaine exerts its stimulant effect by inhibiting dopamine reuptake leading to increased dopamine signaling. This action is thought to reflect binding of cocaine to the dopamine transporter (DAT) to inhibit its function. However, cocaine is a relatively weak inhibitor of DAT, and many DAT inhibitors do not share the behavioral actions of cocaine. We previously showed that toxic levels of cocaine induce autophagic neuronal cell death. Here, we show that subnanomolar concentrations of cocaine elicit neural autophagy in vitro and in vivo. Autophagy inhibitors reduce the locomotor stimulant effect of cocaine in mice. Cocaine-induced autophagy degrades transporters for dopamine but not serotonin in the nucleus accumbens. Autophagy inhibition impairs cocaine conditioned place preference in mice. Our findings indicate that autophagic degradation of DAT modulates behavioral actions of cocaine.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid34121988,

title = {Psychostimulant Use Disorder, an Unmet Therapeutic Goal: Can Modafinil Narrow the Gap?},

author = {Melinda Hersey and Amanda K Bacon and Lydia G Bailey and Mark A Coggiano and Amy H Newman and Lorenzo Leggio and Gianluigi Tanda},

url = {https://pubmed.ncbi.nlm.nih.gov/34121988/},

doi = {10.3389/fnins.2021.656475},

issn = {1662-4548},

year  = {2021},

date = {2021-01-01},

urldate = {2021-01-01},

journal = {Front Neurosci},

volume = {15},

pages = {656475},

abstract = {The number of individuals affected by psychostimulant use disorder (PSUD) has increased rapidly over the last few decades resulting in economic, emotional, and physical burdens on our society. Further compounding this issue is the current lack of clinically approved medications to treat this disorder. The dopamine transporter (DAT) is a common target of psychostimulant actions related to their use and dependence, and the recent availability of atypical DAT inhibitors as a potential therapeutic option has garnered popularity in this research field. Modafinil (MOD), which is approved for clinical use for the treatment of narcolepsy and sleep disorders, blocks DAT just like commonly abused psychostimulants. However, preclinical and clinical studies have shown that it lacks the addictive properties (in both behavioral and neurochemical studies) associated with other abused DAT inhibitors. Clinical availability of MOD has facilitated its off-label use for several psychiatric disorders related to alteration of brain dopamine (DA) systems, including PSUD. In this review, we highlight clinical and preclinical research on MOD and its R-enantiomer, R-MOD, as potential medications for PSUD. Given the complexity of PSUD, we have also reported the effects of MOD on psychostimulant-induced appearance of several symptoms that could intensify the severity of the disease (i.e., sleep disorders and impairment of cognitive functions), besides the potential therapeutic effects of MOD on PSUD.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{TANDA202113,

title = {Modafinil and its structural analogs as atypical dopamine uptake inhibitors and potential medications for psychostimulant use disorder},

author = {Gianluigi Tanda and Melinda Hersey and Briana Hempel and Zheng-Xiong Xi and Amy Hauck Newman},

url = {https://pubmed.ncbi.nlm.nih.gov/32927246/},

doi = {https://doi.org/10.1016/j.coph.2020.07.007},

issn = {1471-4892},

year  = {2021},

date = {2021-01-01},

journal = {Current Opinion in Pharmacology},

volume = {56},

pages = {13 - 21},

abstract = {Pharmacotherapeutics for treatment of psychostimulant use disorder are still an unmet medical goal. Recently, off label use of modafinil (MOD), an approved medication for treatment of sleep disturbances, has been tested as a therapeutic for cocaine and methamphetamine use disorder. Positive results have been found in subjects dependent on psychostimulants without concurrent abuse of other substances. Novel structural analogs of MOD have been synthesized in the search for compounds with potentially broader therapeutic efficacy than the parent drug. In the present report we review their potential efficacy as treatments for psychostimulant abuse and dependence assessed in preclinical tests. Results from these preclinical proof of concept studies reveal that some modafinil analogs do not possess typical cocaine-like neurochemical and behavioral effects. Further, they might blunt the reinforcing effects of psychostimulants in animal models, suggesting their potential efficacy as pharmacotherapeutics for treatment of psychostimulant use disorders.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}